Welcome to our dedicated page for Vistagen Therapeutics SEC filings (Ticker: VTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vistagen Therapeutics, Inc. (Nasdaq: VTGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Vistagen is a Nevada-incorporated, late clinical-stage biopharmaceutical company headquartered in South San Francisco, California, and its filings offer detailed insight into its nose-to-brain neurocircuitry platform, pherine pipeline, governance, and financial condition.
Through documents such as Form 10-K annual reports and Form 10-Q quarterly reports, readers can review Vistagen’s descriptions of its business as a neuroscience-focused biopharmaceutical company, its intranasal pherine product candidates, and the risks and uncertainties associated with late-stage clinical development. These filings also discuss the company’s focus on indications including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause, as well as other women’s health conditions.
Current reports on Form 8-K provide timely information on material events, including clinical and corporate milestones. Recent 8-K filings have addressed topics such as financial results for specific fiscal quarters, progress in the PALISADE Phase 3 program for fasedienol in social anxiety disorder, and changes in executive leadership and board composition. Proxy materials on Form DEF 14A describe matters submitted to a shareholder vote, including director elections, advisory votes on executive compensation, and auditor ratification, along with details about governance practices.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand complex sections on clinical programs, compensation, and shareholder matters. Real-time updates from EDGAR ensure that new Vistagen filings, including any future Forms 4 reporting insider equity awards or transactions, appear promptly, while AI-generated overviews can assist in interpreting how each filing relates to the company’s pherine development strategy and late-stage clinical status.
Vistagen Therapeutics, Inc. (VTGN) filed a Form 4 disclosing an equity award to a senior executive. On 06/23/2025 the company granted its Chief Legal Officer, Reid G. Adler, a non-derivative stock option covering 100,000 shares of common stock at an exercise price of $1.96 per share. The award was issued under Vistagen’s Amended and Restated 2019 Equity Omnibus Incentive Plan.
The option vests in equal monthly installments over three years beginning on the grant date, resulting in full vesting on the three-year anniversary (06/23/2028), and carries a ten-year contractual term expiring 06/23/2035. Following this transaction Mr. Adler beneficially owns 100,000 derivative securities directly, and no open-market purchases or sales of common stock were reported. No 10b5-1 trading plan was indicated. The filing was signed by Cynthia Anderson, Attorney-in-Fact, on 06/25/2025.
Because the disclosure involves a routine incentive grant to a single officer with no immediate cash proceeds or share disposition, it is generally viewed as neutral to mildly positive from a governance standpoint: it aligns executive incentives with long-term shareholder value without altering the public float in the near term.
Vistagen Therapeutics (VTGN) President and CEO Shawn Singh received a significant stock option grant on June 23, 2025. The Form 4 filing discloses:
- Grant of 300,000 stock options to purchase common stock
- Exercise price set at $1.96 per share
- Options expire on June 23, 2035
- Vesting schedule: Equal monthly installments over 3 years starting from grant date
The stock options were granted under the company's Amended and Restated 2019 Equity Omnibus Incentive Plan. This equity compensation aligns the CEO's interests with shareholders through long-term vesting requirements. Singh serves as both President/CEO and Director of Vistagen Therapeutics.
Vistagen Therapeutics (Nasdaq: VTGN) filed an 8-K disclosing a C-suite change under Item 5.02.
- Elissa Cote, age 50, was appointed Chief Corporate Development Officer effective June 23 2025.
- Cote’s background includes senior strategy and BD roles at Mallinckrodt, Sucampo and MedImmune, plus advisory work since 2022.
- The Company executed a customary Indemnification Agreement with Cote, attached as Exhibit 10.1, requiring full indemnity and expense advancement to the maximum extent allowed by Nevada law.
- No related-party transactions or special arrangements were reported.
- Press release announcing the hire is filed as Exhibit 99.1.
No financial metrics were updated; the report is limited to leadership and governance matters.